AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

CG Oncology Inc. Common s... (CGON)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

28.26

0.74 (2.69%)

At close: Feb 20, 2025, 3:59 PM

28.22

-0.14%

After-hours: Feb 20, 2025, 04:00 PM EST

undefined% (undefined)

Bid	27.16
Market Cap	2.15B
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-15.87
PE Ratio (ttm)	-1.78
Forward PE	n/a
Analyst	Buy

Ask	29.3
Volume	267,962
Avg. Volume (20D)	700,422
Open	27.59
Previous Close	27.52
Day's Range	27.23 - 28.71
52-Week Range	25.77 - 48.05
Beta	undefined

About CGON

CG Oncology Inc is a clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. Their product candidate cretostimogene, is initially in clinical development for the treatment of patients with high-risk Non-Muscle Invasive Bladder Cancer who are unresponsive to Bacillus Calmette Guerin (BCG) therapy, the current standard-of-care for high-...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date n/a

Employees 61

Stock Exchange NASDAQ

Ticker Symbol CGON

Full Company Profile

Analyst Forecast

According to 8 analyst ratings, the average rating for CGON stock is "Buy." The 12-month stock price forecast is $65.5, which is an increase of 131.78% from the latest price.

Buy 100.00%

Hold 0.00%

Sell 0.00%

Stock Forecasts

Why Price Moved

1 month ago

+4.34%

CG Oncology shares are trading higher after TD Cow... Unlock content with Pro Subscription

2 months ago

-6.54%

CG Oncology shares are trading lower. The company announced topline data from the Phase 3 BOND-003 trial in patients with high-risk Non-Muscle Invasive Bladder Cancer unresponsive to Bacillus Calmette Guerin.

News

1 month ago · zacks.com

Does CG Oncology, Inc. (CGON) Have the Potential to Rally 123.34% as Wall Street Analysts Expect?

The consensus price target hints at a 123.3% upside potential for CG Oncology, Inc. (CGON). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earning...

2 months ago · seekingalpha.com

CG Oncology: Positive Phase 3 Outcome Could Lead To BLA Of Cretostimogene

CG Oncology, Inc. reported positive phase 3 BOND-003 results for Cretostimogene in treating BCG-unresponsive NMIBC, presented at the SUO 25th Annual Meeting. The company aims to use Cretostimogene as ...

2 months ago · reuters.com

Health Rounds: Experimental CG Oncology immunotherapy shows promise in bladder cancer

An experimental immunotherapy drug is a potentially effective treatment for patients with bladder cancer who no longer respond to current therapies, researchers reported on Thursday at the Society of ...